Despite several reports on the mechanism of the effect of empagliflozin, which has the potential for improved prognosis in heart failure, it is still not fully understood. We experienced a case of left ventricular noncompaction that caused fluid retention in a patient who showed resistance to existing diuretics. By using empagliflozin, we successfully treated this case of acute heart failure and observed stabilized symptoms with no renal dysfunction and deterioration of patient condition. Although the potential for improved prognosis with this drug in a high-risk group for cardiovascular events has been reported, based on EMPA-REG OUTCOME trial results, there are few reports on its effect of treatment and mechanism in treating acute heart failure. The effect of this drug in treating heart failure from the acute phase to the chronic phase can be expected. <Learning objective: Empagliflozin is a drug that works from the acute phase and is effective from the acute phase to the chronic phase, in treating intractable heart failures that demonstrate resistance to existing drug treatments.>.
Keywords: Acute heart failure; Empagliflozin; Sodium glucose cotransporter-2 inhibitor.